Pfizer confirms 177 job cuts at Irish API plants

Pfizer confirms 177 job cuts at Irish API plants
Pfizer has confirmed 177 staff working for production facilities in Ireland will be cut.

In a statement, the firm said the changes would take place during 2013 at its two manufacturing API manufacturing sites in Cork – Little Island and Ringaskiddy.

The news follows poor Q1 results in which the firm reported a 19 per cent drop in revenues.

Patent expiries were fingered as the biggest culprit, most prominently its Lipitor – for cholesterol – which last year attracted the attention of generics makers​ when it became available.

VP Paul Duffy said: “Patent expiry means greater competition which impacts global demand, and we need to readjust the scale of our manufacturing operations.”

However according to RTE news, the firm is still touting Ireland as a “key strategic location”.

Pfizer is now bracing itself for a host of other off-patent hits.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Webinars

Headlines